Abbott Laboratories shares fell 4.8% after fourth-quarter revenue of $11.46 billion missed the $11.8 billion consensus. Earnings per share of $1.50 met estimates, but investors reacted to the shortfall and weak first-quarter guidance. The company projected Q1 EPS of $1.12-$1.18, below the $1.20 analyst expectation.

The Medical Devices segment was a bright spot, with sales rising 12.3% to $5.68 billion. Diabetes Care, including continuous glucose monitors, grew 14.5% to $2.13 billion. Nutrition sales fell 8.9% due to lower volumes and strategic price moves, while Diagnostics revenue dropped 2.5% amid fading COVID-19 testing demand.

For 2026, Abbott forecasts organic sales growth of 6.5%-7.5% and adjusted EPS of $5.55-$5.80, exceeding the analyst consensus of $5.17. CEO Robert B. Ford said the company is positioned for accelerating growth. Investors will watch whether the strong device pipeline can offset ongoing headwinds in nutrition and diagnostics.